Microsoft (MSFT) and pharmaceutical concern Bristol Myers Squibb (BMY) are partnering on a new artificial intelligence (A.I.) technology that speeds up lung cancer detection.
The collaboration will see the companies use A.I. algorithms to analyze X-ray and CT images to help identify lung cancer earlier and more quickly.
Bristol Myers Squibb said in a news release that the A.I. technology could help clinicians spot hard-to-detect lung cancers and identify the disease at earlier and more treatable stages.
Technology giant Microsoft said that it plans to provide access to the early detection technology to underserved rural hospitals and community clinics across the U.S.
Pharmaceutical companies are turning to A.I. to accelerate research and development (R&D) and provide new tools to improve medical outcomes.
Last week, pharma giant AstraZeneca (LON: AZN) announced that it is employing A.I. to speed-up cancer drug research.
Microsoft’s stock has risen 7% over the past year, while Bristol Myers Squibb’s share price has declined 3%.
